Understanding Common IRB Audit Findings in Clinical Trials

Introduction: The Role of IRBs in Clinical Trials

Institutional Review Boards (IRBs) or Ethics Committees (ECs) play a critical role in protecting the rights, safety, and welfare of participants in clinical trials. Regulatory agencies such as the FDA, EMA, and MHRA require IRBs to ensure that trials comply with ethical and scientific standards under ICH GCP. Despite their importance, IRBs frequently appear in regulatory audit reports with recurring deficiencies.

Common IRB audit findings include delays in protocol approvals, incomplete review documentation, poor oversight of ongoing studies, and inadequate handling of Serious Adverse Events (SAEs). These issues undermine trial integrity and expose sponsors and investigators to compliance risks.

Regulatory Expectations for IRBs

Authorities have set specific expectations for IRBs to ensure compliance:

• Review and approve all trial protocols and amendments before implementation.
• Ensure informed consent documents are compliant, accurate, and approved before use.
• Review safety data, including SAEs and SUSARs, in a timely manner.
• Maintain detailed minutes of IRB meetings and decisions.
• Conduct continuing review of ongoing studies at least annually.

The ClinicalTrials.gov registry underscores the role of IRBs in ensuring transparency and ethical oversight in clinical research.

Common IRB Audit Findings in Clinical Trials

1. Delayed Protocol Approvals

Auditors frequently cite IRBs for approving protocols or amendments after trial activities have already started.

2. Incomplete Documentation of Reviews

Inspection reports often highlight missing IRB approval letters or inadequate documentation of meeting deliberations.

3. Failure to Conduct Continuing Review

Auditors commonly note lapses in annual reviews of ongoing trials, a clear non-compliance with ICH GCP.

4. Inadequate SAE Oversight

IRBs are often cited for failing to review SAE or SUSAR reports promptly and comprehensively.

Case Study: FDA Audit on IRB Deficiencies

During an FDA inspection of a Phase II oncology trial, inspectors noted that the IRB failed to review continuing safety reports for over a year. Several amendments were also implemented without prior IRB approval. The FDA classified this as a major deficiency, requiring corrective action by both the sponsor and the IRB.

Root Causes of IRB Audit Findings

Root cause analysis of common IRB audit findings often reveals:

• Resource limitations leading to delayed reviews or incomplete oversight.
• Absence of SOPs for handling continuing review or protocol amendments.
• Poor documentation practices during IRB meetings.
• Lack of training for IRB members on regulatory requirements.
• Weak sponsor oversight of IRB performance and compliance.